Company / Free Cash Flow
AIM ImmunoTech Inc. Free Cash Flow History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$21.3M
FY2024
5-year range
-$21.3M / -$10.4M
FY2020-FY2024
Trend
-31.4%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow has declined for 3 consecutive years, from -$10M in FY2021 to -$21M in FY2024.
Based on SEC 10-K filings.
-$21M in FY2024.
Declined from -$14M to -$21M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- AIM ImmunoTech Inc.'s free cash flow has declined for 3 consecutive years.
- In FY2024, free cash flow decreased 31.4% year-over-year.
- Peak free cash flow was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score -71.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | -$21.3M | -31.4% |
| FY2023 | -$16.2M | -15.6% |
| FY2022 | -$14.0M | -34.8% |
| FY2021 | -$10.4M | +0.0% |
| FY2020 | -$10.4M | -13.7% |
| FY2019 | -$9.1M | +14.6% |
| FY2018 | -$10.7M | +34.4% |
| FY2017 | -$16.3M | -116.1% |
| FY2016 | -$7.5M | +53.7% |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026